Education
About Us
Working with TipRanks
Follow Us
ABLS - ETF AI Analysis
Top Page
Abacus FCF Small Cap Leaders ETF (ABLS)
Rating:70Outperform
Price Target:―
Positive Factors
Strong Lead Holding
The largest position, Argan, has shown strong gains this year, providing a meaningful boost to the fund’s results.
Multiple Sector Exposure
Holdings spread across technology, health care, industrials, financials, and consumer sectors help reduce reliance on any single industry.
Moderate Expense Ratio
The fund’s fee is reasonable for a specialized small-cap strategy, allowing investors to keep more of their potential returns.
Negative Factors
Recent Weak Short-Term Performance
The ETF has experienced weak returns over the past one and three months, which may signal near-term volatility or pressure on small-cap stocks.
High Stock Concentration
A small number of holdings, especially the top position, make up a significant share of the portfolio, increasing the impact of any single stock’s performance.
Limited Geographic Diversification
With almost all assets invested in U.S. companies, the fund offers little protection from risks specific to the U.S. market.
ABLS vs. SPDR S&P 500 ETF (SPY)
AUM956.41K
RegionNorth America
Expense Ratio0.39%
Beta0.77
IssuerAbacus
Inception DateFeb 18, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedAbacus FCF Small Cap Leaders Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume338
30 Day Avg. Volume123
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
23.98Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering51
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ABLS Summary
The Abacus FCF Small Cap Leaders ETF (ABLS) tracks the Abacus FCF Small Cap Leaders Index, focusing on smaller U.S. companies with strong profits and healthy cash flow. It holds a mix of sectors like technology, health care, industrials, and financials, with top positions in firms such as CommVault Systems and Oscar Health. Investors might consider ABLS if they want growth potential from small-cap stocks while still emphasizing financially solid businesses and diversification across many industries. However, small-cap stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.
How much will it cost me?The Abacus FCF Small Cap Leaders ETF (ABLS) has an expense ratio of 0.39%, meaning you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a niche area of small-cap stocks with strong financial metrics.
What would affect this ETF?The Abacus FCF Small Cap Leaders ETF could benefit from strong growth in the U.S. economy, particularly in sectors like technology and health care, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as small-cap companies often rely on borrowing to fund growth, or if economic conditions weaken, which could impact consumer spending and industrial activity. Regulatory changes in key sectors like financials or health care could also influence performance positively or negatively.
ABLS Top 10 Holdings
ABLS is a U.S.-only small-cap fund with a clear tilt toward health care, tech, and industrials, and a few names doing much of the heavy lifting. Argan is the star of the show, with strong, steady gains that have quietly pulled the fund higher, while LCI Industries has also been rising and adding support. On the flip side, CommVault Systems and Harmony Biosciences have been losing steam, weighing on recent results, and Enova International has shown mixed momentum. Overall, it’s a focused small-cap play with a handful of outsized drivers.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Argan | 11.92% | $114.02K | $5.75B | 263.97% | 73 Outperform | |
| Collegium Pharmaceutical | 5.20% | $49.73K | $1.18B | 28.99% | 71 Outperform | |
| Artisan Partners | 4.81% | $46.01K | $3.02B | -13.32% | 73 Outperform | |
| Enova International | 4.08% | $39.05K | $3.44B | 50.34% | 71 Outperform | |
| Healthcare Services | 3.76% | $36.00K | $1.45B | 93.17% | 72 Outperform | |
| LCI Industries | 3.68% | $35.16K | $3.14B | 31.84% | 79 Outperform | |
| Harmony Biosciences Holdings | 3.22% | $30.76K | $1.64B | -15.86% | 81 Outperform | |
| PJT Partners | 3.11% | $29.77K | $3.48B | -3.45% | 71 Outperform | |
| Oscar Health | 3.11% | $29.74K | $4.12B | -13.28% | 49 Neutral | |
| Kontoor Brands | 2.92% | $27.97K | $4.21B | 26.13% | 66 Neutral |
ABLS Technical Analysis
Negative
―
Price Trends
19.76
Negative
20.06
Negative
20.36
Negative
Market Momentum
-0.23
Positive
36.67
Neutral
41.96
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABLS, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 19.22, equal to the 50-day MA of 19.76, and equal to the 200-day MA of 20.36, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 36.67 is Neutral, neither overbought nor oversold. The STOCH value of 41.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABLS.
ABLS Peer Comparison
Comparison Results
Performance Comparison
ABLS
Abacus FCF Small Cap Leaders ETF
18.57
-0.84
-4.33%
AFSM
First Trust Active Factor Small Cap ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
ROSC
Hartford Multifactor Small Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents